データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます
968-93-4C[C@@]12CC[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CCC(=O)O2968-93-4安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。
使用Testolactone USP (Teslac) is used to treat Breast cancer.
一般的な説明Testolactone, 13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acidΔ-lactone (Teslac),was originally synthesized as a possible anabolic steroid,considering its structural similarity to testosterone. The keystructural difference from anabolic steroids is the D-ring lactone instead of the typical cyclopentyl ring. Althoughconsidered in many texts an androgen or anabolic steroid (itis a Schedule III drug because of its classification as an anabolicsteroid), testolactone lacks androgenic effects in vivo.Its action is believed to be caused by irreversible inhibitionof aromatase. It is a relatively weak inhibitor of aromatase,but the irreversible nature of the inhibition can lead to prolongedeffects. Its relatively weak inhibition of aromataseand its undesirable dosage schedule (5×50-mg tabletsq.i.d.) give this older agent only limited use in breast cancertreatment because of better available options.
現在のフィルター条件では反応記録がありません。
読み込み中…